Literature DB >> 15624764

Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors.

Jennifer Brady1, James Neal, Nagarajan Sadakar, Philippe Gasque.   

Abstract

Endosialin (tumor endothelial marker 1) is expressed preferentially by tumor endothelial cells but not by normal endothelium. Its protein domain architecture is homologous to that of CD93 and thrombomodulin (CD141), suggesting a similar function in mediating cell-cell interactions. The aim of this study was to investigate the expression pattern of endosialin in human brain tumors in a bid to decipher its contribution to tumor angiogenesis. We generated an antibody specifically recognizing human endosialin and used it to study endosialin expression in 30 human brain tumor specimens by immunoblotting and immunohistochemistry. Twenty of 30 tumors expressed endosialin in a heterogeneous manner. The largest proportion of endosialin-expressing tumors was found in highly invasive glioblastoma multiforme, anaplastic astrocytomas, and metastatic carcinomas. Endosialin was localized to the endothelium of small and large vessels strongly stained for CD31 and was also expressed by Thy-1-positive fibroblast-like cells close to the meninges and alpha-smooth muscle actin-positive cells in some vessels. Endosialin colocalized with thrombomodulin, suggesting the proteins may have complementary functions in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624764     DOI: 10.1093/jnen/63.12.1274

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  33 in total

1.  A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.

Authors:  Luis A Diaz; Christina M Coughlin; Susan C Weil; Jean Fishel; Mrinal M Gounder; Susan Lawrence; Nilofer Azad; Daniel J O'Shannessy; Luigi Grasso; Jason Wustner; Wolfgang Ebel; Richard D Carvajal
Journal:  Clin Cancer Res       Date:  2014-11-14       Impact factor: 12.531

2.  Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).

Authors:  Robin E Norris; Elizabeth Fox; Joel M Reid; Andrew Ralya; Xiaowei W Liu; Charles Minard; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2018-01-02       Impact factor: 3.167

3.  Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.

Authors:  Anirudh Sattiraju; Akiva Mintz
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.

Authors:  Ann-Marie Chacko; Chunsheng Li; Madhura Nayak; John L Mikitsh; Jia Hu; Catherine Hou; Luigi Grasso; Nicholas C Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

5.  Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.

Authors:  Chunsheng Li; Ann-Marie Chacko; Jia Hu; Kosei Hasegawa; Jennifer Swails; Luigi Grasso; Wafik S El-Deiry; Nicholas Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  Cancer Biol Ther       Date:  2014-02-19       Impact factor: 4.742

6.  Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration.

Authors:  Brian Tomkowicz; Katherine Rybinski; Brian Foley; Wolfgang Ebel; Brad Kline; Eric Routhier; Philip Sass; Nicholas C Nicolaides; Luigi Grasso; Yuhong Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-06       Impact factor: 11.205

7.  Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.

Authors:  John G Facciponte; Stefano Ugel; Francesco De Sanctis; Chunsheng Li; Liping Wang; Gautham Nair; Sandy Sehgal; Arjun Raj; Efthymia Matthaiou; George Coukos; Andrea Facciabene
Journal:  J Clin Invest       Date:  2014-03-18       Impact factor: 14.808

8.  The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferation.

Authors:  Debbie L Hardie; Mathew J Baldwin; Amy Naylor; Oliver J Haworth; Tie Zheng Hou; Sian Lax; S John Curnow; Nick Willcox; John MacFadyen; Clare M Isacke; Christopher D Buckley
Journal:  Immunology       Date:  2011-04-06       Impact factor: 7.397

9.  Characterization of TEM1/endosialin in human and murine brain tumors.

Authors:  Eleanor B Carson-Walter; Bethany N Winans; Melissa C Whiteman; Yang Liu; Sally Jarvela; Hannu Haapasalo; Betty M Tyler; David L Huso; Mahlon D Johnson; Kevin A Walter
Journal:  BMC Cancer       Date:  2009-11-30       Impact factor: 4.430

10.  Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation.

Authors:  Rowan S Hardy; Claudia Hülso; Yingling Liu; Sylvia J Gasparini; Colette Fong-Yee; Jinwen Tu; Shihani Stoner; Paul M Stewart; Karim Raza; Mark S Cooper; Markus J Seibel; Hong Zhou
Journal:  Arthritis Res Ther       Date:  2013-01-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.